MX377669B - Derivados de aminoester. - Google Patents
Derivados de aminoester.Info
- Publication number
- MX377669B MX377669B MX2016015958A MX2016015958A MX377669B MX 377669 B MX377669 B MX 377669B MX 2016015958 A MX2016015958 A MX 2016015958A MX 2016015958 A MX2016015958 A MX 2016015958A MX 377669 B MX377669 B MX 377669B
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- sup
- buffer
- edta
- hci
- Prior art date
Links
- -1 AMINO ESTER Chemical class 0.000 title 1
- 239000000872 buffer Substances 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 abstract 3
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 3
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 3
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 abstract 2
- 230000027455 binding Effects 0.000 abstract 2
- 238000005119 centrifugation Methods 0.000 abstract 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 abstract 2
- 238000002474 experimental method Methods 0.000 abstract 2
- 239000012528 membrane Substances 0.000 abstract 2
- 229960001383 methylscopolamine Drugs 0.000 abstract 2
- 239000008188 pellet Substances 0.000 abstract 2
- 239000002287 radioligand Substances 0.000 abstract 2
- 229940122694 Muscarinic M3 receptor antagonist Drugs 0.000 abstract 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract 1
- 229930006000 Sucrose Natural products 0.000 abstract 1
- 239000007983 Tris buffer Substances 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000001728 clone cell Anatomy 0.000 abstract 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 abstract 1
- 239000002532 enzyme inhibitor Substances 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- LZCOQTDXKCNBEE-IKIFYQGPSA-N methscopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)C)=CC=CC=C1 LZCOQTDXKCNBEE-IKIFYQGPSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000003681 muscarinic M3 receptor antagonist Substances 0.000 abstract 1
- 230000003551 muscarinic effect Effects 0.000 abstract 1
- 230000009871 nonspecific binding Effects 0.000 abstract 1
- 239000002953 phosphate buffered saline Substances 0.000 abstract 1
- 238000000159 protein binding assay Methods 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 239000005720 sucrose Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 abstract 1
- 238000005406 washing Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14171266 | 2014-06-05 | ||
| PCT/EP2015/062417 WO2015185649A1 (en) | 2014-06-05 | 2015-06-03 | Aminoester derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016015958A MX2016015958A (es) | 2017-04-10 |
| MX377669B true MX377669B (es) | 2025-03-11 |
Family
ID=50884281
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016015958A MX377669B (es) | 2014-06-05 | 2015-06-03 | Derivados de aminoester. |
Country Status (32)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR104532A1 (es) | 2015-05-07 | 2017-07-26 | Chiesi Farm Spa | Derivados aminoéster como inhibidores de la fosfodiesterasa 4 (pde4) y antagonistas de los receptores m3 |
| AR104822A1 (es) * | 2015-06-01 | 2017-08-16 | Chiesi Farm Spa | Derivado de aminoésteres |
| TW201710254A (zh) * | 2015-06-01 | 2017-03-16 | 吉斯藥品公司 | 胺基酯衍生物 |
| CN106866474B (zh) * | 2017-02-16 | 2018-12-28 | 陕西师范大学 | 一种手性α-芳基甘氨酸酯衍生物的合成方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2022783A1 (en) | 2007-08-08 | 2009-02-11 | CHIESI FARMACEUTICI S.p.A. | "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors" |
| PE20091552A1 (es) | 2008-02-06 | 2009-10-25 | Glaxo Group Ltd | Farmacoforos duales - antagonistas muscarinicos de pde4 |
| EP2216327A1 (en) | 2009-02-06 | 2010-08-11 | CHIESI FARMACEUTICI S.p.A. | Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors |
| AR093797A1 (es) | 2012-12-05 | 2015-06-24 | Chiesi Farm Spa | Derivados de feniletilpiridina inhibidores de pde-4 |
| KR20150091061A (ko) | 2012-12-05 | 2015-08-07 | 키에시 파르마슈티시 엣스. 피. 에이. | Pde4-억제제로서 페닐에틸피리딘 유도체 |
| KR20150092173A (ko) | 2012-12-05 | 2015-08-12 | 키에시 파르마슈티시 엣스. 피. 에이. | Pde4-억제제로서 페닐에틸피리딘 유도체 |
| WO2015082619A1 (en) | 2013-12-05 | 2015-06-11 | Chiesi Farmaceutici S.P.A. | Benzhydryl derivatives for the treatment of respiratory diseases |
| KR20160086351A (ko) | 2013-12-05 | 2016-07-19 | 키에시 파르마슈티시 엣스. 피. 에이. | 호흡기 질환의 치료를 위한 헤테로아릴 유도체 |
-
2015
- 2015-05-28 US US14/723,964 patent/US9763924B2/en not_active Expired - Fee Related
- 2015-06-03 RS RS20181192A patent/RS57787B1/sr unknown
- 2015-06-03 EA EA201692227A patent/EA032761B1/ru not_active IP Right Cessation
- 2015-06-03 DK DK15731261.2T patent/DK3152201T3/en active
- 2015-06-03 PE PE2016002520A patent/PE20161557A1/es unknown
- 2015-06-03 HR HRP20181967TT patent/HRP20181967T1/hr unknown
- 2015-06-03 PT PT15731261T patent/PT3152201T/pt unknown
- 2015-06-03 SI SI201530392T patent/SI3152201T1/sl unknown
- 2015-06-03 ES ES15731261.2T patent/ES2688826T3/es active Active
- 2015-06-03 JP JP2016571037A patent/JP2017516824A/ja not_active Withdrawn
- 2015-06-03 MA MA39947A patent/MA39947B1/fr unknown
- 2015-06-03 TN TN2016000546A patent/TN2016000546A1/en unknown
- 2015-06-03 WO PCT/EP2015/062417 patent/WO2015185649A1/en not_active Ceased
- 2015-06-03 BR BR112016026725-7A patent/BR112016026725B1/pt not_active IP Right Cessation
- 2015-06-03 SG SG11201610132RA patent/SG11201610132RA/en unknown
- 2015-06-03 LT LTEP15731261.2T patent/LT3152201T/lt unknown
- 2015-06-03 KR KR1020167032346A patent/KR102420323B1/ko active Active
- 2015-06-03 CN CN201580029748.7A patent/CN106459020B/zh not_active Expired - Fee Related
- 2015-06-03 GE GEAP201514338A patent/GEP20186922B/en unknown
- 2015-06-03 EP EP15731261.2A patent/EP3152201B1/en active Active
- 2015-06-03 MX MX2016015958A patent/MX377669B/es active IP Right Grant
- 2015-06-03 PL PL15731261T patent/PL3152201T3/pl unknown
- 2015-06-03 HU HUE15731261A patent/HUE042119T2/hu unknown
- 2015-06-03 AU AU2015270539A patent/AU2015270539B2/en not_active Expired - Fee Related
- 2015-06-03 CA CA2953198A patent/CA2953198C/en active Active
- 2015-06-04 AR ARP150101772A patent/AR100732A1/es unknown
- 2015-06-04 TW TW104118107A patent/TW201625600A/zh unknown
-
2016
- 2016-11-09 PH PH12016502221A patent/PH12016502221A1/en unknown
- 2016-12-01 IL IL249325A patent/IL249325B/en not_active IP Right Cessation
- 2016-12-02 ZA ZA2016/08331A patent/ZA201608331B/en unknown
- 2016-12-02 CL CL2016003117A patent/CL2016003117A1/es unknown
-
2017
- 2017-08-10 US US15/673,710 patent/US10117860B2/en active Active
-
2018
- 2018-09-24 CY CY181100984T patent/CY1120698T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016502221A1 (en) | Aminoester derivatives | |
| Farley et al. | Identification and quantification of protein posttranslational modifications | |
| CA2868907C (en) | Anti-hla-b*27 antibodies and uses thereof | |
| MX2015008024A (es) | Anticuerpos anti-tau humanos. | |
| HK1223629A1 (zh) | Bcma及cd3结合分子 | |
| WO2013177118A3 (en) | Novel purification of non-human antibodies using protein a affinity chromatography | |
| HK1256737A1 (zh) | 通过改变细胞表面信号和信号比选择性扩增不同的t细胞亚群 | |
| MY182355A (en) | Hmo synthesis | |
| MY175254A (en) | Synthesis of lactams | |
| WO2010039802A3 (en) | Methods and compositions for isolating nucleic acid | |
| WO2011056975A3 (en) | Genetically encoded calcium indicators and methods of use | |
| EP4570924A3 (en) | Chromophore-based characterization and detection methods | |
| MX2011009025A (es) | Sistema de vector de expresion que comprende dos marcadores de seleccion. | |
| Sołtysik et al. | ERα36–another piece of the estrogen puzzle | |
| WO2010114239A3 (ko) | 도로의 면형 데이터를 이용한 맵 매칭장치 및 그 방법 | |
| WO2010128518A3 (en) | Novel process for the preparation of cisatracurium besylate | |
| BRPI0915574A2 (pt) | sequência nucleotídica, construção nucleotídica, célula ou linhagem celular, método para produção de fibrinogênio em um sistema de cultura de célula eucariótica, preparação de fibrinogênio, uso da preparação de fibrinogênio, método para seleção de célula ou linhagem celular | |
| WO2012082742A3 (en) | Detecting cancer with anti-ccl25 and anti-ccr9 antibodies | |
| Jean-Charles et al. | Chapter nine-cellular roles of beta-arrestins as substrates and adaptors of ubiquitination and deubiquitination | |
| WO2011143575A3 (en) | smFRET WITH MEMBRANE PROTEINS | |
| WO2012040603A3 (en) | Use of diazolidinyl urea for anti-clumping of biological samples | |
| MX336940B (es) | Uso de compuestos mejoradores de señal en deteccion de electroquimioluminiscencia. | |
| WO2012168344A8 (en) | BINDING COMPOUNDS TO HUMAN β1-ADRENORECEPTOR (β1-AR) AND THEIR USE IN THE MEASUREMENT OF AUTO-ANTI-βA1-AR ANTIBODIES | |
| WO2011055897A3 (en) | Fusion protein binding specifically to constant region of antibody, preparation thereof and method for isolating antibody using the same | |
| WO2013085540A3 (en) | Cry crystals for the production of antimicrobial proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |